Becton, Dickinson and Co. (BDX) traded lower on Wednesday, April 29, 2026, extending a fragile sentiment backdrop into the company’s next catalyst: fiscal second-quarter results expected April 30, 2026. With the name already under pressure in recent months following a guidance reset tied in part to Alaris, incremental caution ahead of the print has driven selling in the shares.

BD’s Alaris infusion-pump franchise continues to act as a headline and confidence overhang, with investors repeatedly keying off regulatory and recall-related developments. The FDA’s device recall information for BD Alaris infusion sets shows updates as recently as April 17, 2026, and the agency has also flagged recall/correction communications around Alaris as among the most serious types, keeping attention elevated into earnings.

BDX’s recent drawdowns have been linked to concerns about FY2026 expectations after earlier guidance changes tied to Alaris dynamics, making the next report a high-leverage check-in for both execution and outlook. Against that backdrop, any sign of slower remediation progress, additional quality costs, or timing impacts to U.S. infusion pump commercialization could disproportionately affect near-term sentiment.